PROKIDNEY CORP (PROK) Stock Price & Overview
NASDAQ:PROK • US74291D1046
Current stock price
The current stock price of PROK is 1.9 USD. Today PROK is up by 8.57%. In the past month the price decreased by -19.15%. In the past year, price increased by 217.04%.
PROK Key Statistics
- Market Cap
- 571.577M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.52
- Dividend Yield
- N/A
PROK Stock Performance
PROK Stock Chart
PROK Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PROK. When comparing the yearly performance of all stocks, PROK is one of the better performing stocks in the market, outperforming 95.57% of all stocks.
PROK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PROK. Both the profitability and financial health of PROK have multiple concerns.
PROK Earnings
On March 18, 2026 PROK reported an EPS of -0.14 and a revenue of 225.00K. The company missed EPS expectations (-12.87% surprise) and beat revenue expectations (47.06% surprise).
PROK Forecast & Estimates
15 analysts have analysed PROK and the average price target is 6.63 USD. This implies a price increase of 248.95% is expected in the next year compared to the current price of 1.9.
For the next year, analysts expect an EPS growth of 4.04% and a revenue growth -55.95% for PROK
PROK Groups
Sector & Classification
PROK Financial Highlights
Over the last trailing twelve months PROK reported a non-GAAP Earnings per Share(EPS) of -0.52. The EPS increased by 17.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.56% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PROK Ownership
PROK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PROK
Company Profile
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
Company Info
IPO: 2021-06-30
PROKIDNEY CORP
2000 Frontis Plaza Blvd, Suite 250
Winston-Salem NORTH CAROLINA US
Employees: 204
Phone: 13369997028
PROKIDNEY CORP / PROK FAQ
What does PROKIDNEY CORP do?
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
What is the current price of PROK stock?
The current stock price of PROK is 1.9 USD. The price increased by 8.57% in the last trading session.
Does PROKIDNEY CORP pay dividends?
PROK does not pay a dividend.
How is the ChartMill rating for PROKIDNEY CORP?
PROK has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is PROK stock listed?
PROK stock is listed on the Nasdaq exchange.
Can you provide the growth outlook for PROKIDNEY CORP?
The Revenue of PROKIDNEY CORP (PROK) is expected to decline by -55.95% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does PROKIDNEY CORP have?
PROKIDNEY CORP (PROK) currently has 204 employees.